Skip to Content

Posts tagged with "Infectious Diseases"

  • Business and Markets

    A (Busy) Day in the Life

    I’d like to recommend this article by Lisa Jarvis at C&E News – she’s following along with Forge Therapeutics, a small startup specializing in metalloprotease inhibitors, as they make it through a day at the recent J. P. Morgan conference in San Francisco. It’s an accurate and realistic look at a world that not everyone… Read More
  • Infectious Diseases

    Fun With Priority Review Vouchers

    So in that last post, I mentioned a Priority Review Voucher as a likely reason for Marin Shkreli’s latest machinations, and that makes me think that I should explain what the heck a Priority Review Voucher is, since it’s an obscure topic if you’re not into the ins and outs of regulatory drug approval. It’s… Read More
  • Business and Markets

    Shkreli’s Chagas Maneuver

    In case you’ve been wondering what Martin Shkreli has been up to, here’s a look at his recent appearance at a meeting put on by the folks at Forbes. “Unrepentant” would be an appropriate adjective, although I can think of some others, along with some richly descriptive nouns. He has been backing out of his statements… Read More
  • Cancer

    Antibiotics: Not As Easy As They Say

    Since we were just talking yesterday about antibiotics and the misconceptions that people have about them, this is an appropriate time to take a look at an article in the popular press about antibiotic discovery. ( counts as “popular press”, for sure). The article focuses on the work of Brian Murphy at UI-Chicago, who’s do… Read More
  • Infectious Diseases

    A Mistake About Making Mistakes

    Most of the people reading this blog have some knowledge of chemistry and/or biology. (Not everyone, though – I get email from readers with no formal training who just stop by to hear what’s going on, and I’m very happy to have them). But if you do know a lot about a subject, any subject… Read More
  • Drug Development

    Idiocy On Drug Research Costs

    Here’s a piece from the Center for Economic and Policy Research that claims to have the whole high-drug-price problem figured out. It’s “incredibly inefficient research”, just so you know. How does the CEPR know, you ask? They do a comparison of the costs of research (as provided by the Center for the Study of Drug Developm… Read More
  • Drug Industry History

    C-Nucleosides Never Went Away

    Here’s a paper in J. Med. Chem. calling for a revival of work in the C-nucleoside area. To some extent, these compounds never went away, but it’s certainly true that there was a period where many more groups were working on them. When I was looking for an undergraduate research project to do during my… Read More
  • Alzheimer's Disease

    A Fungal Origin For Alzheimer’s?

    Here’s a potentially interesting paper that’s recently appeared, saying that numerous brain regions in Alzheimer’s patients appear to show signs of fungal infection, as opposed to control samples. The authors claim detection through antibodies, and to have isolated fungal DNA as well, identifying several species. The authors (from… Read More
  • Infectious Diseases

    Does An Ancient Retrovirus Have Anything to Do with ALS?

    One of the reasons that many people think that organisms can carry around “junk” DNA (that has little or no function) is that up to 8% of our own genomes are remnants of ancient retroviruses. At some points in the distant past, some germ-line cells got infected, had viral DNA spliced into them, and then… Read More
  • Chemical News

    Natural Products Drug Discovery Wins a Nobel

    This year’s Physiology/Medicine Nobel has gone to three discoverers of important drugs for topical diseases: William C. Campbell and Satoshi Ōmura for Avermectin, and Youyou Tu for Artemisinin. I last wrote about artemisinin here, with reference to a scale-up synthesis. And scale-up is a useful topic with that one, because it’s one… Read More